BOSTON, Feb. 6, 2019 /PRNewswire/ -- Proteostasis Therapeutics,
Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking
therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced
that Emmanuel Dulac, PharmD, Ph.D., and Kim Cobleigh Drapkin, CPA, have been appointed to the
Company's Board of Directors.
Dr. Dulac joined Alnylam Pharmaceuticals in August 2016 as Chief Commercial Officer to establish
the company's global commercial organization. He has over twenty years of international biotechnology and pharmaceutical industry
expertise, launching and marketing multiple drugs, including cystic fibrosis products. Ms. Drapkin is the Chief Financial Officer
at Jounce Therapeutics, Inc. She has over two decades of financial leadership experience working with private and publicly traded
biotechnology and pharmaceutical companies, establishing financial infrastructure, raising capital and leading strategic
financial planning.
"Emmanuel and Kim are seasoned life sciences leaders and we are fortunate to welcome them to PTI's board of directors," said
Meenu Chhabra, President and Chief Executive Officer of Proteostasis. "Collectively, Emmanuel's clinical development
and commercial expertise, particularly in cystic fibrosis, and Kim's experience working for a broad range of growing biotech
companies, will provide PTI valuable insight as we approach multiple key data readouts of our proprietary combinations and add-on
CF therapies."
Prior to Alnylam, Dr. Dulac led the Rare Disease Business Unit at Shire and held several leadership roles of increasing
responsibility at Novartis, Abbott and Sanofi. Notably, he led the clinical trials, global regulatory approvals and global launch
of TOBI® podhaler for cystic fibrosis patients. During his career, Dr. Dulac has built successful sales, patient
services, marketing and market access organizations. He has launched five brands and led two blockbuster drugs globally. He
graduated from the University of Paris XI with a Doctorate in Pharmacology (PharmD, Ph.D.) and completed an MBA from
the ESSEC School in Paris.
"PTI is an emerging leader in cystic fibrosis, a disease area in which I have significant clinical, commercial background and
personal connections. I'm excited to join the board and contribute to the development of these promising new treatment options
for CF patients," commented Dr. Dulac.
Prior to her role at Jounce, Ms. Drapkin owned a financial consulting firm, where she served as Interim CFO for numerous early
stage biotechnology companies, including Avila Therapeutics, Blueprint Medicines, Eleven Biotherapeutics, NinePoint Medical, and
Voyager Therapeutics. Prior, Ms. Drapkin served as CFO of EPIX Pharmaceuticals for four years. For the preceding ten years, she
served at Millennium Pharmaceuticals, Inc. as Director of Finance, with leadership responsibility for financial reporting,
technical accounting, internal audit and Sarbanes Oxley initial implementation and compliance. Ms. Drapkin began her career in
the technology and life sciences practice at PriceWaterhouseCoopers LLP. She earned her B.S. from Babson
College and is a Certified Public Accountant.
"I am pleased to be joining the PTI board of directors and I look forward to sharing my financial leadership experience with
the other board members and the management team to support the strategic growth of the Company," commented Ms. Drapkin.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat
cystic fibrosis and other diseases caused by dysfunctional protein processing. Headquartered in Boston,
MA, the Proteostasis Therapeutics team focuses on identifying therapies that restore protein function. For more
information, visit www.proteostasis.com.
Safe Harbor
To the extent that statements in this release are not historical facts, they are forward-looking statements reflecting the
current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Words such as "aim," "may," "will," "expect," "anticipate," "estimate," "intend," and similar
expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to
identify forward-looking statements. Examples of forward-looking statements made in this release include, without
limitation, statements regarding the potential of our proprietary combination therapies for the treatment of CF, the
potential benefit to patients of our proprietary combination therapies, expected timing of the data from our clinical studies and
our expectations regarding our new board members. Forward-looking statements made in this release involve substantial risks
and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking
statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or
achieved. Such risks and uncertainties include, without limitation, the uncertainties inherent in the execution and
completion of clinical trials, in the timing of availability of trial data, in the results of the clinical trials, in the actions
of regulatory agencies, in the commercialization and acceptance of new therapies, and those set forth in our Quarterly Report on
Form 10-Q for the quarter ended September 30, 2018 and our other SEC filings. We assume no obligation
to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACTS:
Investors:
David Pitts / Claudia Styslinger
Argot Partners
212.600.1902
[email protected] / [email protected]
Media:
David Rosen
Argot Partners
212.600.1902
[email protected]
View original content:http://www.prnewswire.com/news-releases/proteostasis-therapeutics-appoints-emmanuel-dulac-and-kim-drapkin-to-board-of-directors-300790736.html
SOURCE Proteostasis Therapeutics, Inc.